Last reviewed · How we verify

NCT05317429: GlyCarb

Glycaemic Responses to Carbohydrate-rich Meals (GlyCarb)

ENROLLING BY INVITATION NA Last updated 24 July 2025
What this trial tests

NA trial testing A meal delivering 75 g of carbohydrate in Glycaemia in 25 participants. Enrolling by invitation.

Timeline
14 February 2022
Primary endpoint
31 March 2028
30 June 2028

Quick facts

Lead sponsorQuadram Institute Bioscience
PhaseNA
StatusENROLLING BY INVITATION
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingdouble
Primary purposebasic science
Enrollment25
Start date14 February 2022
Primary completion31 March 2028
Estimated completion30 June 2028
Sites1 location across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

Quadram Institute Bioscience

Who can join

18 and older, any sex, with Glycaemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Carbohydrate-rich foods such as potatoes, bread, rice, pasta, breakfast cereals, biscuits and other snacks are a major component of the human diet. The effect of different carbohydrate-rich foods on blood sugar (glucose) levels after a meal varies between foods. This is relevant to health because studies have shown that regular intake of carbohydrate foods that cause large increases in blood glucose levels after ingestion can be detrimental to metabolic health. The aim of the GlyCarb study is to investigate how food structure influences postprandial glycaemic responses to carbohydrate foods. This will be achieved through a series of acute postprandial studies (up to 5 studies), wherein healthy participants within each postprandial study consume a pair of carbohydrate-rich test meals while wearing a continuous glucose monitoring system (CGM). Each postprandial study will use the same GlyCarb Remote standard protocol, where a randomised cross-over design is used to measure the glycaemic response to two carbohydrate-rich test meals, one "test" and one "control". Both meals will be matched by carbohydrate content, contain similar ingredients and have a similar physical appearance, but will differ in one key food property (e.g., altered food structure) to test its effect on postprandial glycaemia. In each postprandial study, habitual dietary intake and body composition will be captured at baseline as part of the participant characterisation. Participants will consume two different carbohydrate-rich test meals twice, on separate occasions, in a randomly allocated order over a 10 to 14-day period of continuous glucose monitoring. Data from the continuous glucose monitors will be used to assess the postprandial glycaemic response to each carbohydrate food. The participants will be required to complete brief questionnaires designed to evaluate differences in palatability (taste, texture, portion size) and satiety amongst test meals. Study participant feedback will be requested at the end of the study and used to assess and improve future study procedures. The GlyCarb study will enable new understanding of how food properties influence glycaemic responses to different types of carbohydrate foods. Ultimately, the findings will inform the rational design or reformulation of food products and diets to support a healthy glucose metabolism.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Effect of wheat bread with elevated amylose on postprandial glycaemic response: a randomised crossover trial delivered remotely using continuous glucose monitoring.
    Corrado M, Savva GM, Ahn-Jarvis JH, Oyeyinka SA, et al · · 2025 · PMID 41277638 · DOI 10.1039/d5fo03147h

Verify or expand the search:

Other Quadram Institute Bioscience trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05317429.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing